Astatine (211At) is an alpha-emitter with a better treatment efficacy against differentiated thyroid cancer compared with iodine (131I), a conventional beta-emitter. However, its therapeutic comparison has not been fully evaluated. In this study, we compared the therapeutic effect between [211At]NaAt and [131I]NaI. In vitro analysis of a double-stranded DNA break (DSB) and colony formation assay were performed using K1-NIS cells. The therapeutic effect was compared using K1-NIS xenograft mice administered with [211At]NaAt (0.4 MBq (n = 7), 0.8 MBq (n = 9), and 1.2 MBq (n = 4)), and [131I]NaI (1 MBq (n = 4), 3 MBq (n = 4), and 8 MBq (n = 4)). The [211At]NaAt induced higher numbers of DSBs and had a more reduced colony formation than [131I]NaI. In K1-NIS mice, dose-dependent therapeutic effects were observed in both [211At]NaAt and [131I]NaI. In [211At]NaAt, a stronger tumour-growth suppression was observed, while tumour regrowth was not observed until 18, 25, and 46 days after injection of 0.4, 0.8, and 1.2 MBq of [211At]NaAt, respectively. While in [131I]NaI, this was observed within 12 days after injection (1, 3, and 8 MBq). The superior therapeutic effect of [211At]NaAt suggests the promising clinical applicability of targeted alpha therapy using [211At]NaAt in patients with differentiated thyroid cancer refractory to standard [131I]NaI treatment.
Using the data sample of collected with the Belle detector operating at the KEKB asymmetric-energy collider, we present the results of an investigation of the and invariant mass distributions looking for substructure in the decay . We find a significant signal in each mass distribution. When interpreted as resonances, we find for the () combination a mass of [], an intrinsic width of [] with a significance of (). As these two signals are very close to the threshold, we also investigate the possibility of a cusp, and find that we cannot discriminate between these two interpretations due to the limited size of the data sample.
We investigate the chiral phase transition in the strong coupling lattice QCD at finite temperature and density with finite coupling effects. We adopt one species of staggered fermion, and develop an analytic formulation based on strong coupling and cluster expansions. We derive the effective potential as a function of two order parameters, the chiral condensate and the quark number density , in a self-consistent treatment of the next-to-leading order (NLO) effective action terms. NLO contributions lead to modifications of quark mass, chemical potential, and the quark wave function renormalization factor. While the ratio is too small in the strong coupling limit, it is found to increase as increases. The critical point is found to move in the lower direction as increases. Since the vector interaction induced by is shown to grow as , the present trend is consistent with the results in Nambu-Jona-Lasinio models. The interplay between two order parameters leads to the existence of partially chiral restored matter, where effective chemical potential is automatically adjusted to the quark excitation energy.
The was searched for via the reaction using the 1.2 GeV/ beam at the K6 beam line of the KEK-PS 12 GeV Proton Synchrotron. In the missing mass spectrum of the reaction, no clear peak structure was observed. Therefore a 90% C.L. upper limit of 3.5 μb/sr was derived for the differential cross section averaged over to in the laboratory frame of the reaction. This upper limit is much smaller than the theoretical calculation for the -channel process where a is exchanged. From the present result, either the -channel process is excluded or the coupling constant of g is quite small.
The processes and are studied using initial-state-radiation events in a sample of collected with the Belle detector at the KEKB asymmetric-energy collider. The cross sections from the mass threshold to and the effective form factors of and are measured. In the charmonium region, we observe the decays and and determine the respective branching fractions.
Chronic subdural hematoma (CSDH) is an angiogenic disease that is involved with many inflammatory mediators. Tie2 is predominantly expressed in the embryonic endothelium and plays an important role in the maturation and stabilization of the vasculature. Angiopoietin (Ang)1 and Ang2 are well-known ligands of the Tie2 receptor. We examined the expression of Ang1 and Ang2 in CSDH fluid and the expression of Tie-2 receptor and components of the angiogenic signaling pathways in the outer membrane of CSDH. Twenty-five samples of CSDH fluid and eight samples of outer membrane of CSDH were included. The concentrations of Ang1 and Ang2 in the CSDH fluid were measured using enzyme-linked immunosorbent assay (ELISA) kits. The expression of Tie2, phosphoinositide 3-kinase (PI3K), protein kinase B (Akt) mechanistic target of rapamycin (mTOR), GβL, 70 kDa ribosomal protein S6 kinase (p70S6K), eukaryotic initiation factor 4E (eIF-4E), and β-actin was examined by a Western blot analysis. The expression of Tie2, Akt, and mTOR was also examined by immunohistochemistry. The concentration of Ang2 in CSDH fluid was significantly higher than that in the serum or cerebrospinal fluid (CSF), and also higher than that of Ang1 in CSDH fluid. Tie2, PI3K, Akt, mTOR, GβL, p70S6K, and eIF-4E were detected in all cases. In addition, Tie2, Akt, and mTOR were localized in the endothelial cells of vessels in the CSDH outer membrane. Our data suggest that Ang2, although not Ang1, in CSDH fluid promotes angiogenesis in endothelial cells through the Tie2 receptor. The Ang2/Tie2 signaling pathway might therefore be a useful therapeutic target for treating the growth of intractable CSDH.